EUVIMEDEUVIMED entdecken
Open Access

[ 161 Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [ 177 Lu]Lu-PSMA-617

Andrea Schaefer-Schuler, Caroline Burgard, Arne Blickle, Stephan Maus, Christine Petrescu, Sven Petto, Mark Bartholomä, Tobias Stemler, Samer Ezziddin, Florian Rosar

Theranostics · 2024

DOI: 10.7150/thno.92273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2024. Verfasst von Andrea Schaefer-Schuler und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Saarland University, Medical Center, Homburg, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 60-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Evaluation of alternative radionuclides for use in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is currently focusing on 161Tb, which may provide advantages by emitting additional Auger and conversion electrons. In this pilot study, we present preliminary dosimetry data for [161Tb]Tb-PSMA-617 RLT in a direct comparison with [177Lu]Lu-PSMA-617.

Method

Six patients with metastatic castration-resistant prostate cancer (mCRPC) underwent treatment with [177Lu]Lu-PSMA-617 and subsequently - after inadequate response - with [161Tb]Tb-PSMA-617. Whole-body planar and SPECT imaging-based dosimetry of organs at risk (kidneys and salivary glands) and tumor lesions were calculated using IDAC for 177Lu and OLINDA/EXM for 161Tb. The therapeutic index (TI) of mean tumor-absorbed doses over relevant organs at risk was calculated.

Results

Mean absorbed doses to organs at risk of PSMA-RLT were slightly higher for [161Tb]Tb-PSMA-617 compared to [177Lu]Lu-PSMA-617 (kidneys: 0.643 ± 0.247 vs. 0.545 ± 0.231 Gy/GBq, factor 1.18; parotid gland: 0.367 ± 0.198 vs. 0.329 ± 0.180 Gy/GBq, factor 1.10), but markedly higher regarding tumor lesions (6.10 ± 6.59 vs 2.59 ± 3.30 Gy/GBq, factor 2.40, p < 0.001). Consequently, the mean TI was higher for [161Tb]Tb-PSMA-617 compared to [177Lu]Lu-PSMA-617 for both, the kidneys (11.54 ± 9.74 vs. 5.28 ± 5.13, p = 0.002) and the parotid gland (16.77 ± 13.10 vs. 12.51 ± 18.09, p = 0.008).

Conclusion

In this intra-individual head-to-head pilot study, [161Tb]Tb-PSMA-617 delivered higher tumor-absorbed doses and resulted in superior TI compared to [177Lu]Lu-PSMA-617. This preliminary data support 161Tb as a promising radionuclide for PSMA-RLT in mCRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantMaleHumansPilot ProjectsRadiopharmaceuticalsDipeptidesProstate-Specific AntigenHeterocyclic Compounds, 1-RingRadioisotopesLutetium

Stichwörter der Autor:innen

161TbPSMAdosimetrymCRPCprostate cancerradioligand therapy

Substanzen

PSMA-617RadiopharmaceuticalsDipeptidesProstate-Specific AntigenHeterocyclic Compounds, 1-RingRadioisotopesLutetium

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Saarland University, Medical Center, Homburg, Germany.

Zitieren

APA

Schaefer-Schuler, A., Burgard, C., Blickle, A., Maus, S., Petrescu, C., Petto, S., Bartholomä, M., Stemler, T., Ezziddin, S., & Rosar, F. (2024). [ 161 Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [ 177 Lu]Lu-PSMA-617. Theranostics. https://doi.org/10.7150/thno.92273

Vancouver

Schaefer-Schuler A, Burgard C, Blickle A, Maus S, Petrescu C, Petto S, et al. [ 161 Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [ 177 Lu]Lu-PSMA-617. Theranostics. 2024. doi:10.7150/thno.92273

BibTeX
@article{SchaeferSchuler2024,
  author = {Schaefer-Schuler, Andrea and Burgard, Caroline and Blickle, Arne and Maus, Stephan and Petrescu, Christine and Petto, Sven and Bartholomä, Mark and Stemler, Tobias and Ezziddin, Samer and Rosar, Florian},
  title = {[ 161 Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [ 177 Lu]Lu-PSMA-617},
  journal = {Theranostics},
  year = {2024},
  doi = {10.7150/thno.92273}
}
Kostenlos starten →